A THOROUGH REVIEW OF MISOPROSTOL USE IN POSTPARTUM HEMORRHAGE ASSOCIATED WITH PREGNANCY-INDUCED HYPERTENSIVE DISORDERS

Abstract

Postpartum hemorrhage, characterized by significant blood loss following delivery, poses a severe risk to maternal well-being. Defined as blood loss exceeding 500ml after vaginal delivery and 1000ml after cesarean section within 24 hours of childbirth, this condition is particularly prevalent among pregnant women with hypertensive pregnancy syndrome. Hypertensive pregnancy syndrome, marked by hypertension developing after 20 weeks' gestation with accompanying proteinuria or organ dysfunction, is a key risk factor for postpartum hemorrhage. The multifaceted etiology of postpartum hemorrhage involves inadequate uterine contractions, often triggered by high blood pressure and vascular irregularities. These factors impede endometrial contraction and hemostatic capabilities, elevating the risk of bleeding. Additionally, hypertensive syndrome during pregnancy can lead to coagulation abnormalities, further diminishing blood clotting and increasing the vulnerability to bleeding. Swift and effective management of postpartum hemorrhage is imperative, as untreated cases can have dire consequences, including endangering the lives of pregnant individuals. Hence, close monitoring and prompt intervention in cases of postpartum hemorrhage in pregnancy-induced hypertensive syndrome are vital components of maternal healthcare.